Citadel Advisors
EFTR

Citadel Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Citadel Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-531
Closed -$187K – 15013
2021
Q3 		$187K Sell
531
-23,621
-98% -$7.62M ﹤0.01% 12084
2021
Q2 		$5.97M Buy
24,152
+14,853
+160% +$3.65M ﹤0.01% 4069
2021
Q1 		$2.26M Buy
+9,299
New +$2.28M ﹤0.01% 6103

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's EFTR Position: Q4 2021 in Review

Citadel Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2021, closing a stake of 531 shares — an estimated $187K sold.

Citadel Advisors first reported a position in EFTR in Q1 2021 and held it in 3 quarters. The position peaked at $5.97M in Q2 2021. 18 funds tracked by Wall St. Rank hold EFTR as of Q4 2021.

  • Citadel Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Citadel Advisors sold 531 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $187K.
  • Citadel Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Citadel Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $5.97M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.